Long-Term Follow-Up Study of Patients Who Have Received Gene-Modified Cell Therapy Produced by Ex Vivo Transduction of Immune Cells Expressing Viral or Non-Viral Vector in Trials
Enrolling By Invitation
99 years or below
All
Phase
N/A
1 Location
Brief description of study
This is an observational follow-up study of patients who have been exposed to a CAR-T cell treatment that was produced by ex vivo transduction with a CAR-expressing retroviral vector in studies sponsored by Sorrento Therapeutics, Inc.
Patients are to be followed for up to 15 years after exposure to a retroviral CAR-T cell agent for the possible development of long-term adverse events and efficacy outcomes.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: CAR-T,gene-modified cell therapy
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 844613
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
